Abstract
A Phase II study of vincristine (NSC 67574) in pathologic categories 1, 3 and 4 (WHO) bronchogenic carcinoma was performed. Partial objective responses were observed in 5 of 15 patients with adenocarcinoma. Responses were observed in pulmonary masses ( 5 15 ), metastasic cervical nodes ( 2 5 ) and ( 2 5 ) and hepatic metastases ( 1 2 ). Median survival for patients presenting a response to VCR was 339 days, compared to 73 days for non-responders. Only 1 of 10 patients with epidermoid carcinoma and none of 10 patients with anaplastic-large cell carcinomas responded to VCR therapy. It was concluded VCR is active in adenocarcinoma of lung and it might deserve further evaluation in Phase III trials.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
